Mirati Submits MAA to the EMA for Adagrasib (MRTX849) to Treat KRASG12C-Mutated Non-Small Cell Lung Cancer
Shots:
- The company has submitted an MAA to the EMA for adagrasib in patients with NSCLC harboring KRASG12C mutation who have received one prior systemic therapy
- The MAA was based on the registration enabling cohort of the P-II (KRYSTAL-1) study evaluating adagrasib (600mg, BID) in patients with advanced NSCLC. The results will be presented at ASCO 2022
- Adagrasib is a highly selective, and potent oral small-molecule inhibitor of KRASG12C that is optimized to sustain target inhibition while adagrasib’ NDA is currently under US FDA’s review for accelerated approval & is being reviewed under the RTOR pilot program to enable the safe and effective treatments to patients shortly
Ref: PRNewswire | Image: Mirati Therapeutics
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
